GT Biopharma announced the appointment of Shawn Cross as president and COO of the company.
GT Biopharma (OTCQB:GTBP) announced the appointment of Shawn Cross as president and COO of the company.
As quoted in the press release:
Mr. Cross is an internationally recognized investment banker specializing in the biopharmaceutical sector with over 20 years of experience. He was most recently Managing Director, Head of Biotechnology Investment Banking at Deutsche Bank Securities Inc. Previously, he served as Managing Director and Head of Biopharmaceutical Investment Banking at Wells Fargo Securities, LLC.
Mr. Cross began his career at Alex. Brown & Sons Inc. after receiving his M.B.A. with a concentration in Finance from Columbia Business School. He received his B.S. from University of California, Los Angeles and prior to business school worked in Brian Reid’s lab at the University of Washington Medical School, Division of Gastroenterology, where he worked on a team studying the role of p53 in neoplastic progression.
GT Biopharma Executive Chairman Anthony J. Cataldo said, “The addition of Shawn to our executive management team is important to continuing to advance the accomplishments we have achieved throughout this year. Shawn’s experience in advising publicly traded emerging biotech companies, in key strategic arenas, provides timely expertise at this stage of the Company’s growth and serves as a major milestone for the Company.”